Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Phenomen Pharma
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07068191CT.gov Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fatty Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ursodeoxycholic Acid (this asset) | Phenomen Pharma | N/A | D · 30 |
| Metformin | Leiden University Medical Center | P4 | BBB |
| Alpha Tocopherol | Yuen Kah Hay | P4 | BB |
| Rilpivirine | Fundacion SEIMC-GESIDA | P4 | BB |
| Pioglitazone | Seoul National University Bundang Hospital | P4 | BB |
| Raltegravir | Helsinki University Central Hospital | P4 | BB |
| Empagliflozin | Seoul National University Bundang Hospital | P4 | BB |
| Dolutegravir | Fundacion SEIMC-GESIDA | P4 | BB |
| Liraglutide | Leiden University Medical Center | P4 | BB |
+42 more in the Fatty Liver Disease cohort
Other indications for Ursodeoxycholic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Biliary Cholangitis | — | P4 | A · 82 |
| Cirrhosis Of Liver | — | P3 | BBB · 72 |
| Type 2 Diabetes Mellitus | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ursodeoxycholic Acid in Fatty Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ursodeoxycholic-acid-fatty-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →